Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
First Merchants Corporation announced that CEO Mark K. Hardwick will retire effective January 1, 2027, after 29 years with the company. Michael J. Stewart, the current President of First Merchants Bank, has been appointed to succeed him as President and Chief Executive Officer as part of a planned executive succession plan. Stewart has been with the bank for over 18 years and will assume the principal executive officer role upon Hardwick's retirement.
Azitra, Inc. has completed Cohort 1 of its Phase 1/2 clinical trial for ATR-04, a live biotherapeutic candidate for treating skin rash associated with EGFR inhibitors. Following a safety review committee clearance, the company is proceeding to enroll approximately 24 patients in Cohort 2 to further evaluate safety, tolerability, and preliminary efficacy.
Aptera Motors announced a significant reduction in its estimated capital requirements to reach production, lowering the target to $25 million from a previous estimate of $40-$45 million. The company attributes these savings to its strategic partnership with Launch Design, which improved manufacturability and supplier access, and now expects to begin building its first 40 production vehicles by the end of 2026.
Counterparty
Shanghai Launch Automotive Technology Co., Ltd.
“This is a fundamentally leaner path to getting Aptera into customers’ hands. We’ve reduced our estimated capital requirements to reach production and brought what we believe could be a self-sustaining business within much closer reach.”
Chris Anthony, Co-CEO of Aptera
“By redesigning the Aptera for manufacturability and tapping Launch Design’s international supplier network, we believe we are pursuing one of the more capital-efficient paths to production in the EV industry.”
Airgain, Inc. appointed Stephan D. Memmen to its Board of Directors as a Class II director, effective October 1, 2026, increasing the board size from seven to eight members. In connection with his appointment, Mr. Memmen received $50,000 in restricted stock units and $50,000 in stock options, both vesting over three years, along with standard cash compensation for non-employee directors. Mr. Memmen brings extensive industry experience from prior leadership roles at Amphenol Corporation and Pulse Electronics.
Evommune presented Phase 2a proof-of-concept data for EVO301 in patients with moderate-to-severe atopic dermatitis, showing a 55% mean reduction in EASI scores at Week 12 compared to 22% for placebo. The trial validated IL-18 inhibition as a novel therapeutic approach with a favorable safety profile, and the company plans to initiate a Phase 2b dose-ranging trial in mid-2027.
Counterparty
European Academy of Dermatology and Venereology (EADV)
Strategy Inc's board of directors declared semi-monthly cash dividends of $0.50 per share on its Variable Rate Series A Perpetual Stretch Preferred Stock (STRC), representing a 12.00% annual rate. The dividends are payable on October 31 and November 15, 2026, though the November payment is contingent on the outcome of a stockholder vote regarding Daily Dividend Amendments. The company intends to maintain the 12.00% rate until the preferred stock demonstrates sustained trading near $100 per share.
Radnostix Divestiture to Nano Nuclear Energy Inc. for $13.5M
Radnostix Inc. entered into a definitive agreement to sell its depleted uranium deconversion and fluorine extraction assets, including an NRC license and related patents, to Nano Nuclear Energy Inc. for $13.5 million. The consideration consists of $9.5 million in cash and $4 million in Nano Nuclear restricted common stock, allowing Radnostix to focus on its core radioisotope technology segments.
Allarity Therapeutics provided an operational update regarding its proprietary Drug Response Predictor (DRP) technology, patent portfolio, and in-house laboratory capabilities. The company highlighted that higher DRP scores were associated with longer overall survival in ovarian cancer patients treated with stenoparib, supporting its strategy to use the technology for patient selection in upcoming pivotal trials.
Nektar Therapeutics announced long-term Phase 2b data for rezpegaldesleukin in patients with alopecia areata (REZOLVE-AA) and atopic dermatitis (REZOLVE-AD) at the EADV Congress 2026. The data demonstrated sustained hair regrowth and deepening of response even six months after treatment cessation, suggesting a differentiated regulatory T cell (Treg) mechanism compared to existing systemic therapies.
USA Rare Earth, Inc. has completed its CEO succession plan, with Thras Moraitis officially assuming the role of Chief Executive Officer. Moraitis, who previously served as the company's President, succeeds Barbara Humpton and will focus on integrating the company's global rare-earth business units following the combination with Serra Verde.
Filana Therapeutics President & CEO Richard Barry Buys $278K of Stock
Richard Barry, President & CEO, bought 306,813 shares of Filana Therapeutics, Inc. at $0.9 to $0.92 a share (average $0.9065) in 2 transactions, worth $278K in total between Sep 29, 2026 and Sep 30, 2026. Shares held after the trade: 1,337,964 (+8.1%).
Armada Acquisition Corp. II M&A Deal with Ripple Labs Inc.
Armada Acquisition Corp. II shareholders approved the business combination with Ripple Labs Inc. and Pathfinder Digital Assets LLC at an extraordinary general meeting. The transaction involves a merger and domestication of the company from the Cayman Islands to Delaware, where it will be renamed Arrington Capital SPAC I Inc. Approximately 69% of the shares entitled to vote were represented at the meeting to approve the deal.
Veritone, Inc. entered into a securities purchase agreement for a registered direct offering of 20,000,000 shares of common stock at an implied price of $0.75 per share. The company expects to raise $15.0 million in gross proceeds to repay or restructure convertible debt and for general corporate purposes. The offering is expected to close on or about October 2, 2026.
Jonathan Vassil has notified Toast, Inc. of his decision to step down as Chief Revenue Officer, effective December 31, 2026. The departure is described as a planned retirement and not the result of any disagreement with the company. Mr. Vassil will remain with the company in a non-executive capacity through April 2, 2027.
Brightline Interactive closed a private investment in public equity (PIPE) raising $1.25 million in gross proceeds through the issuance of units of common stock and warrants. The financing was led by drone industry executive Dr. Allan Evans in his personal capacity to support the development of the SpatialCore Physical AI platform.
Valion Bio announced the successful completion of formulation work for a novel oral mucosal version of its radiation protection biologic, Entolimod, using Shear Kershman Laboratories' BioViscid platform. This milestone creates a potential needle-free delivery pathway that could significantly expand the addressable market for radiological emergency deployment. The company plans to move into studies testing systemic delivery into the bloodstream next.
Vylor Inc. announced the final results of its private exchange offers to swap three series of senior notes issued by EIDP, Inc. for new senior notes issued by Vylor. Approximately $1.44 billion in total principal amount was validly tendered, representing high participation rates across the 2030, 2032, and 2033 notes. The exchange is part of Corteva's planned separation into two independent companies, with settlement expected to occur simultaneously with the separation on October 1, 2026.
Corteva's subsidiary Vylor Inc. announced the final results of private exchange offers for three series of EIDP, Inc. senior notes totaling approximately $1.44 billion in principal amount. The exchange is part of Corteva's planned separation into two independent companies, with the new Vylor Notes expected to be issued simultaneously with the consummation of the separation.
Monte Rosa Therapeutics announced positive Phase 1 results for MRT-8102, a NEK7-directed molecular glue degrader for inflammatory diseases. The GFORCE-1 study in 108 subjects showed 80-90% NEK7 degradation and normalization of key ASCVD pathogenic drivers with a favorable safety profile, supporting the planned initiation of multiple Phase 2 studies in coronary artery disease, gout, and hidradenitis suppurativa.
Civista Bancshares, Inc. has appointed Mark J. Sams as Senior Vice President and Chief Revenue Officer for both the holding company and Civista Bank. Sams, who has over 25 years of banking experience, will oversee Treasury Management, Wealth Management, Private Banking, and other strategic growth initiatives.
Chesapeake Utilities Corporation has entered into an Equity Distribution Agreement to establish an at-the-market (ATM) equity offering program. The program allows the company to sell up to $225 million of its common stock from time to time, though no shares have been sold as of the filing date. Proceeds are intended for general corporate purposes, including capital expenditures and debt repayment.
McCormick reported Q3 2026 financial results with net sales increasing 17.4% to include 1.9% organic growth and significant contribution from the McCormick de Mexico acquisition. While GAAP EPS fell to $0.36 from $0.84 due to one-time items, adjusted EPS rose to $0.86, and the company reaffirmed its full-year 2026 outlook.
Term
Q3 2026
Earnings call
Oct 1, 2026, 8:00 AM ET
“Third quarter results demonstrate the resilience and differentiated performance of our flavor-focused business model in a dynamic operating environment. We delivered strong sales growth, including organic growth across our global flavor portfolio, while expanding our profit margins.”
Brendan M. Foley, Chairman, President, and CEO
“Looking ahead, our enhanced margin profile and operational discipline position us to continue investing in our brands, capabilities, and innovation to support organic sales growth and drive long-term shareholder value creation.”
FrontView REIT provided an operational update for Q3 2026, reporting the acquisition of 16 properties for $50.6 million at a 7.6% yield and the sale of 5 properties for $17.1 million. The company also disclosed capital markets activity, including the settlement of ATM forward shares for $32.7 million and the issuance of $20.0 million in Series A Convertible Preferred Stock.
Kyntra Bio appointed Andrew E. Singer to its Board of Directors and Audit Committee, effective October 1, 2026. Simultaneously, Maykin Ho, Ph.D. resigned from the Board after nearly eight years of service. The company also renewed a change-in-control and severance agreement with CEO Thane Wettig for a three-year term with no material changes to compensation.
Acuity Inc. reported fiscal fourth-quarter and full-year 2026 results, with annual net sales increasing 7% to $4.6 billion. The company achieved significant earnings growth, with full-year diluted EPS rising 36% to $17.05 and strong operating cash flow of $826 million.
Term
FY2026
Earnings call
Oct 1, 2026, 8:00 AM ET
“We demonstrated solid execution in the fourth quarter of fiscal 2026. We grew sales and expanded our adjusted operating profit and adjusted operating profit margin. We increased our adjusted diluted earnings per share, generated strong cash flow and allocated capital effectively”
Neil Ashe, Chairman, President and Chief Executive Officer
“Throughout fiscal 2026 we strengthened Acuity Brands Lighting while continuing to scale Acuity Intelligent Spaces, building the operating and financial capacity needed to compound growth and value over time.”
Neil Ashe, Chairman, President and Chief Executive Officer
Slam Corp. issued an Amended and Restated Consolidated Promissory Note to its sponsor, consolidating ten existing promissory notes totaling approximately $15.5 million. The new note introduces an interest rate equal to the prime rate and matures in five years, with an option for the company to settle the debt in Class A ordinary shares.
Keurig Dr Pepper has appointed Russ Torres as CEO of its Coffee Operating Unit, effective November 3, 2026. Torres will eventually serve as CEO of Global Coffee Co., the standalone entity expected to be formed following the company's planned separation of its coffee and beverage businesses in early 2027. He joins from Kimberly-Clark, where he served as President and Chief Operating Officer.
Russell Torres, the President and Chief Operating Officer of Kimberly-Clark Corporation, notified the company on September 29, 2026, that he will depart effective November 2, 2026. He is leaving the corporation to pursue other opportunities.
Fervo Energy has achieved commercial operation at its first 33 MW GeoBlock at Cape Station in Utah, marking the world's first greenfield enhanced geothermal development to reach this milestone. The facility was built in 23 months and is now generating revenue under a power purchase agreement, with two additional Phase I GeoBlocks expected to go online by January 2027.
Ovintiv Inc. received approval from the Toronto Stock Exchange to renew its normal course issuer bid (NCIB) to repurchase up to 26,973,037 common shares, representing 10% of its public float. The program will run from October 5, 2026, to October 4, 2027, as part of the company's commitment to return 60% of its 2026 Non-GAAP Free Cash Flow to shareholders.